ADVA
14.12.2020 09:02:08 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the continuing expansion of its Ensemble Harmony Ecosystem . With the addition of 20 members, the industry’s leading network functions virtualization (NFV) partner program features an even broader range of virtualized applications and supported services. New additions to the multi-vendor ecosystem include cloud, virtualization, networking and security leader, VMware. Communication service providers (CSPs) can now benefit from open solutions developed by over 65 members, including more than 50 virtual network functions (VNFs) and more than 40 white box servers.
“We’re excited to be joining the Ensemble Harmony Ecosystem, helping it accelerate the pace of NFV innovation and generate new value for our customers. This program is key to creating the openness and interoperability needed in the new age of software-based telecommunication networks,” said Mark Vondemkamp, VP, Products, SD-WAN and SASE Business, VMware. “For us, the Ensemble Harmony Ecosystem enables comprehensive virtualized solutions. It enables CSPs to choose from a wide variety of commercial VNFs and effortlessly realize the promise of NFV. Ensemble Harmony also makes it easy for us to deliver a consistent cloud architecture all the way from the public cloud to the network edge.”
ADVA’s Ensemble Harmony Ecosystem is a coalition of hardware, software and service partners working together to drive virtualization and softwarization in telecommunication networks. The program delivers everything CSPs require to harness the full benefits of NFV and automation. It fosters close collaboration between partners to ensure interoperability and provides the ability to select from industry-leading solutions, including the most popular SD-WAN, firewall and WAN optimization products. Aside from VMware, the most recent additions to the Ensemble Harmony Ecosystem are CASwell, flexiWAN, IEI Integration Corp, NEXCOM and Lanner.
“Lanner continues to work with ADVA on CSP adoption of NFV. And our support and promotion of Ensemble Harmony is another great example of how we together provide solutions that outperform purpose-built platforms in every way,” said Sven Freudenfeld, CTO, Lanner Inc. “Lanner’s Whitebox Solutions™, coupled with Ensemble and VNF partners, provide solutions that are available off-the-shelf, with the best technology, pre-validated, and fully homologated.”
“This ongoing growth means our Ensemble Harmony Ecosystem provides more options and delivers more value. By welcoming industry leaders like VMware into the program, we’re enabling our customers to transform their operations with some of the best available cloud solutions,” commented James Buchanan, GM, Edge Cloud, ADVA. “Today’s CSPs demand the freedom to choose the most advanced virtualization technology from a variety of leading innovators. They expect tech suppliers to cooperate with each other to ensure interoperability and reduce complexity. That’s what our Ensemble Harmony Ecosystem is all about. It creates an environment that fosters close cooperation, accelerates new initiatives and enables true multi-vendor solutions.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
VMware, and VMware SD-WAN are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions. All other marks and names mentioned herein may be trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005045/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom